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Human Bocavirus 
in Infants, New 
Zealand 
To the Editor: In 2005, a par-
vovirus, subsequently named human 
bocavirus (HBoV), was discovered in 
respiratory samples taken from infants 
and children hospitalized at Karo-
linksa University Hospital, Sweden, 
with lower respiratory tract infection 
(1). HBoV has since been identiﬁ  ed in 
infants and children with respiratory 
illness in >17 countries, at frequencies 
ranging from 1.5% to >18.0%. 
In the past decade New Zealand 
has experienced increasing bronchiol-
itis hospitalization rates, currently >70 
admissions per 1,000 infants. To de-
termine the contribution of HBoV to 
New Zealand’s bronchiolitis disease 
prevalence, we tested samples col-
lected from infants hospitalized with 
community-acquired bronchiolitis (2) 
during 3 consecutive winter epidemics 
(June to October, 2003; July to Octo-
ber, 2004; and June to October, 2005) 
in Wellington, NZ, for HBoV by PCR. 
The Central Regional Ethics Commit-
tee approved the study. Written, in-
formed consent was obtained from the 
parent or guardian. 
Demographic, clinical, and labo-
ratory data were collected during hos-
pitalization. Ethnicity of those who 
ascribe to >1 group was determined 
by using a national census method 
that prioritizes ethnicity as follows: 
Māori>Paciﬁ  c>Other>New  Zealand 
European. Oxygen requirement was 
determined to be the best measure of 
bronchiolitis severity (2). Infants who 
needed assisted ventilation or con-
tinuous positive airway pressure were 
classiﬁ  ed severe; those who required 
oxygen supplementation moderate; 
and infants who were hospitalized but 
did not require supplemental oxygen 
mild. 
Nucleic acid was extracted from 
thawed nasopharyngeal aspirates 
(stored at 80°C) by using a High Pure 
Viral Nucleic Acid kit (Roche Diag-
nostics, Auckland, NZ). The HBoV 
nonstructural protein (NP-1) gene was 
ampliﬁ  ed by using primers 188F (5′-
GAGCTCTGTAAGTACTATTAC-3′) 
and 542R (5′-CTCTGTGTTGACT-
GAATACAG-3′) (1) with Expand High 
Fidelity DNA Polymerase (Roche Di-
agnostics, Basel, Switzerland) for 35 
cycles. Products (354 bp) were puri-
ﬁ  ed and sequenced from primers 188F 
and 542R on an ABI3730 Genetic 
Analyzer by using a BigDye Termina-
tor version 3.1 Ready Reaction Cycle 
Sequencing kit (Applied Biosystems, 
Foster City, CA, USA). Sequences 
were submitted to GenBank under ac-
cession nos. EF686006–13. 
Alignments of NP-1 gene se-
quences from nucleotides (nt) 2410–
2602, and NP-1 predicted amino acid 
sequences from amino acids (aa) 1–97 
were constructed by using ClustalW 
version 1.83 (available from www.
ebi.ac.uk/tools/clustalw/index.html) 
and compared with HBoV prototype 
sequences from GenBank (DQ00495-
6). Nasopharyngeal aspirates were 
also screened for respiratory syncytial 
virus (RSV) by reverse transcription–
PCR (RT-PCR) and nested PCR (3) 
and for human metapneumovirus (4), 
inﬂ  uenza A (H1, H3), and inﬂ  uenza B 
by RT-PCR (5). 
Eight (3.5%) of 230 samples, col-
lected from infants hospitalized with 
bronchiolitis during the 2003–2005 
winter epidemic seasons, were posi-
tive for HBoV. In 5 HBoV-positive 
infants no other pathogens were iden-
tiﬁ   ed, but RSV was detected in 3 
(Table). The 8 HBoV-positive infants 
had a median age of 9.5 months, and 
the male:female ratio was 1:1. The 
median length of hospital stay was 5.5 
(range 1–16) days. 
As expected, because HBoV NP-
1 is highly conserved, sequence varia-
tion among New Zealand isolates and 
the prototype Stockholm ST-1 and 
ST-2 (1) NP-1 sequences was limited. 
Alignments of the partial NP-1 se-
quence (nt 2410–2602) of New Zea-
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land isolates with those of ST-1 and 
ST-2 were identical, except for a G→
A change at nt 176 in 2 New Zealand 
isolates (from infants 5 and 8 years 
of age), which resulted in a predicted 
amino acid exchange of S→N at aa 
59. In addition, an A→T change at nt 
274 in all 8 NZ isolates resulted in a 
predicted amino acid substitution of 
T→S at aa 92, a change that has been 
reported previously in Japanese iso-
lates (6).
This study reafﬁ  rms previous re-
ports of ﬁ  nding HBoV in a subset of 
infants with bronchiolitis (7). It is also, 
to our knowledge, the ﬁ  rst study of its 
kind in New Zealand infants, conﬁ  rm-
ing wide distribution of HBoV. In the 
northern hemisphere, HBoV circulates 
primarily during the winter months, 
although it continues circulating until 
early summer, later than most other 
seasonal respiratory viruses (8). There-
fore, this study may underestimate the 
percentage of New Zealand infants 
with bronchiolitis whose HBoV test 
results were positive because sample 
collection ceased in October (south-
ern hemisphere spring) at the end of 
the bronchiolitis epidemic. The small 
number of HBoV-positive infants 
prevents conclusions concerning eth-
nicity, coinfection, and bronchiolitis 
severity.
Although detection of viral nucle-
ic acid by PCR in infants with bronchi-
olitis does not prove that the virus is 
the cause of the disease, it raises a hy-
pothesis worthy of investigation. Fur-
ther studies are required to determine 
the role of HBoV as a human patho-
gen. Although coinfection is common, 
HBoV detection appears to be infre-
quent in asymptomatic controls (9). 
In our study RSV was detected in 3 
(37.5%) HBoV-positive samples. We 
may have underestimated additional 
coinfection because we did not test for 
several respiratory agents, including 
parainﬂ  uenza viruses, rhinoviruses, or 
the newly discovered coronaviruses. 
Finally, HBoV has recently been 
detected in fecal samples (10). Be-
cause 3 HBoV-positive infants had 
diarrhea in addition to bronchiolitis, 
knowing prevalence of HBoV in fecal 
specimens from asymptomatic New 
Zealand children and in those with 
acute gastroenteritis would be of in-
terest. 
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Table. Summary of 8 infants with human bocavirus infection hospitalized with bronchiolitis, New Zealand, 2003–2005* 
Infant
no.
Date
admitted
Sex/ 
age,
mo Ethnicity
Attended
daycare?
Length of 
hospital
stay, d
Illness
severity Apnea
Underlying 
conditions/
comorbitities
RSV
subtype
Highest
temp.,
°C
Enteritic
symptoms
1J u l
2003
M/9 Pacific No 16 Mod – – A 40.1 Diarrhea
2A u g
2003
F/4 Pacific No 6 Sev – – B 38.4 Diarrhea
3S e p
2003
F/11 NZ
European
N o 1 M o d ––– 3 8 . 1 –
4S e p
2003
F/10 Pacific No 4 Sev – 33 weeks’ 
gestation
– 38.3 Diarrhea
5A u g
2004
M/8 Pacific No 2 Mod – Haemophilus 
influenzae 
conjunctivitis
– 37.7 –
6J u l
2005
M/10 Chinese No 10 Mod – 34 weeks’ 
gestation,
repaired
esophageal
atresia and 
tracheomalacia
– 37.7 –
7A u g
2005
F/9 Pacific No 9 Sev + 30 weeks’ 
gestation
A 39.2 –
8S e p
2005
M/13 NZ
European
Yes 5 Mod – Hydronephrosis, 
Pseudomonas 
aeruginosa
urinary tract 
infection
– 37.4 –
*Temp., temperature; Mod, moderate; Sev, severe; –, absent; NZ, New Zealand; +, present. LETTERS
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nz 
Lyme Disease 
in Urban Areas, 
Chicago
To the Editor: Lyme disease is a 
multisystem illness caused by infec-
tion with the tickborne spirochete Bor-
relia burgdorferi. Most infections in 
the United States occur in the North-
east and upper Midwest, and the mid-
western focus now includes Illinois 
(1,2). Previously, the greatest risk of 
contracting Lyme disease in the Mid-
west was conﬁ  ned to the northernmost 
states (Wisconsin and Minnesota) and 
did not encroach into heavily popu-
lated areas around the city of Chicago. 
However, we showed recently that B. 
burgdorferi–infected Ixodes scapular-
is ticks were recovered from sites in 
Cook and DuPage counties (3), but the 
percentages of infected ticks were low 
(<5%). Since that time, however, re-
ports of Lyme disease in Cook County 
have been reviewed and individual I. 
scapularis tick submissions from Lake 
County, north of Chicago, have been 
received. We therefore surveyed new 
areas north of Chicago (closest was <1 
mile from the city limits; farthest was 
≈25 miles from the city limits) and ex-
amined additional ticks for infection 
with B. burgdorferi.
From December 2006 to May 
2007, we collected 172 adult I. scapu-
laris ticks from sites to the north and 
northwest of Chicago (Figure). Adult 
ticks were collected because nymph-
al ticks are more difﬁ  cult to obtain, 
and the infection rate in adult ticks 
is similar (1). The tick midguts were 
removed aseptically, inoculated into 
tubes containing 1 mL of modiﬁ  ed 
Barbour-Stoenner-Kelly medium (4), 
incubated at 35ºC, and examined for 
spirochetes for up to 3 weeks. Spiro-
chetes were recovered from 21 (32%) 
of 65 ticks and 40 (37%) of 107 ticks 
collected from sites in Cook and Lake 
counties, respectively.  In addition, 
PCR using primers speciﬁ  c for outer 
surface protein A (5) conﬁ  rmed that 
the spirochetes were B. burgdorferi.
The  ﬁ   ndings demonstrate that 
the midwestern endemic focus of 
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Figure. Sites surrounding Chicago from which Borrelia burgdorferi–infected  Ixodes 
scapularis ticks were recovered in 2005–2006 () and 2006–2007 (z).